Researchers have launched a study to evaluate drugs prescribed to infants, children and adolescents with Covid-19.
The effort uses an existing trial and will be funded by the National Institutes of Health, the agency said in a statement on Wednesday.
“As we search for safe and effective therapies for Covid-19, we want to make sure that we do not overlook the needs of our youngest patients who may respond differently to these drugs, compared to adults,” Dr. Diana W. Bianchi, director of NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development, said in the statement.
The study is designed to gather information to refine dosing and improve safety, not to evaluate which drug is best, according to the announcement. Researchers will use blood samples to understand the movement of drugs through children’s bodies and collect information on potential side effects and outcomes.
Physicians often prescribe drugs off-label to children, as they have not been specifically tested for use in children. Off-label use is when a US Food and Drug Administration-approved drug is used for an unapproved purpose.
The study is not a clinical trial with a control group. It will investigate a number of drugs that are already given to children with Covid-19. Health care providers who are already treating patients can enroll these patients into the study with parent or guardian approval.